Anti-Malarial Research Continues with Grant
BOSTON - Paratek Pharmaceuticals has received a Phase I Small Business Innovative Research grant from the National Institute of Allergy and Infectious Diseases to research novel tetracycline derivatives for activity against Plasmodium falciparum.
"Doxycycline, a form of tetracycline, has been used against malaria for years, both to treat and prevent malaria," says Ken Takana, PHD, Paratek's vice president of research and development. "We want to add new tetracyclines to the public health arsenal that offer improvements over doxycycline and other current therapies."
The company has a variety of research interests, including antimalarial drugs. Officials are examining the non-antibiotic properties of tetracyclines as antifungals, anti-inflammatories, neuroprotectives and other applications.
It is estimated that malaria infects 300 million globally, killing more than 1 million annually.
For more information, visit: www.paratekpharm.com.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
